Who
Brian N. Cherry
Director
Company insider
Files Form 4 as: Director, Atara Biotherapeutics; Director, Zymeworks.
In numbers
- Trades disclosed
- 8
- Buys
- 1
- Sells
- 0
- Bought
- $2.0M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 12 Jan 2026
- Last trade
- 4 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 4 Sep 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $1000K104,166 at $9.60 | filing |
| 4 Sep 2026filed 4 Sep 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $1000K104,166 at $9.60 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,400 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 12 Jan 2026filed 13 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,400 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.